NCT04151667 2026-03-11
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
Clinical Trials
24 trialsNCT03500445 2025-10-03
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
University of Chicago
Phase 2 Active not recruiting
NCT03314636 2025-08-08
CONPET
Oslo University Hospital
Phase 2 Active not recruiting
NCT04052880 2025-07-20
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
Icahn School of Medicine at Mount Sinai
Phase 2 Active not recruiting
NCT04891809 2025-04-10
Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Active not recruiting
NCT06863584 2025-03-07
SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT04782687 2025-01-16
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
US Oncology Research
Phase 2 Active not recruiting
NCT00482261 2024-11-08
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT03289299 2023-12-12
ASCENT
International Myeloma Foundation
Phase 2 Active not recruiting
NCT00305812 2023-08-04
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
Canadian Cancer Trials Group
Phase 2 Completed
NCT03641456 2023-06-18
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Sun Yat-sen University
Phase 2 Unknown
NCT05147493 2022-03-29
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
Phase 2 Unknown
NCT04065789 2022-01-27
KyDaR
Tel-Aviv Sourasky Medical Center
Phase 2 Completed
NCT00538733 2021-05-24
T-BiRD
Weill Medical College of Cornell University
Phase 2 Completed
NCT01245673 2020-04-06
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
University of Pennsylvania
Phase 2 Completed
NCT00772915 2020-01-18
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT01647165 2019-12-12
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00538824 2018-06-06
DexTR
Weill Medical College of Cornell University
Phase 2 Terminated
NCT02041325 2016-05-17
Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias
Boston VA Research Institute, Inc.
Phase 2 Completed
NCT01501370 2016-05-10
ZLd_Ld
University of Turin, Italy
Phase 2 Withdrawn
NCT00567229 2015-11-20
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00445484 2015-08-24
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00564889 2013-05-14
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Mayo Clinic
Phase 2 Completed
NCT00478218 2011-08-31
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 2 Completed